(Adnkronos) - AstraZeneca e Alexion presentano a Bari uno studio di The European House Ambrosetti sull’impatto che il settore farmaceutico e in particolare il gruppo riescono a generare in Italia.
Category
🗞
NewsTranscript
00:00A contribution to the PIL that exceeds 524 million euros, a total of revenues that in 2023 reached 770 million.
00:11AstraZeneca and Alexion present in Bari a study by The European House and Brusetti on the impact that the pharmaceutical sector, in particular the group, can generate in Italy.
00:21The current economic dimension of AstraZeneca and Alexion is the result of a constant growth path in the last quinquennium.
00:27The revenues in Italy have had an increase of 19.5 from 2019 to 2023.
00:32The growth has been accompanied by an equally virtuous path in the ability to create added value.
00:38The impact that has been shown is an indirect and direct impact of more than 500 million euros of added value in 2023.
00:46A very important factor, a multiplier of almost 3, which means that every euro we have invested has generated almost 2.7 euros of impact on the country's system.
00:57A weight that also serves as a draw for research in this area.
01:00The group boasts a leadership also in the field of rare diseases.
01:03An example is the role of Primo Piano that Alexion plays in the research on myasthenia gravis, with more than 23% of all experiments in progress in this pathology in high therapeutic need.
01:15Today we have 22 studies abroad in Italy and we collaborate with 130 centers in Italy precisely to try to develop new molecules and new indications.
01:27Ambrosetti, who curated the study, underlined how this sector is going through a phase of strong dynamism.
01:34We certainly need to invest to increase the attractiveness of our country system with targeted investments, with a vision of an iScience strategy.